Kite Pharma (KITE): Reiterating Buy Ahead of ZUMA-1 Study - Stifel

September 22, 2016 7:15 AM EDT
Get Alerts KITE Hot Sheet
Price: $46.21 -1.7%

Rating Summary:
    14 Buy, 2 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 26 | Down: 29 | New: 38
Trade KITE Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Stifel analyst, Thomas Shrader, reiterated his Buy rating on shares of Kite Pharma (NASDAQ: KITE) ahead of top-line data from the interim analysis of the ZUMA-1 study, due by the end of the month.

The analyst noted that conversations with clinicians that treat these patients suggest that a CR rate above 25% would be impressive and highly approvable. Conventional salvage chemotherapy in these patients would be expected to produce a CR rate of around 8%.

Based on the first seven patients treated, Kite has reported a CR rate of 57%. The analyst believes that expecting to keep up this pace might be unrealistic and he would view a CR rate of 40% (five times current SOC) to be exciting despite being lower than earlier-stage studies conducted in single centers where no physician learning curve was involved.

No change to the price target of $74.

For an analyst ratings summary and ratings history on Kite Pharma click here. For more ratings news on Kite Pharma click here.

Shares of Kite Pharma closed at $55.58 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities


Add Your Comment